Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Microvasc Res. 2014 Jul 18;95:124–130. doi: 10.1016/j.mvr.2014.07.005

Figure 1.

Figure 1

Dose-response relationship of MAP. For the HBOC solutions, HBOC-201 (N = 6), MP50 (N = 6) and LP50A (N = 8), the sequence of doses was intended to reach the following target cell-free hemoglobin concentrations (monomer basis) in the blood: Dose 1, 2 mg/kg or ~1 μM; Dose 2, 22 mg/kg or ~10 μM; Dose 3, 230 mg/kg or ~100 μM; and Dose 4, 780 mg/kg or ~300 μM. For the volume control, HSA (N = 8) corresponded to the four doses of HBOC solutions: Dose 1, 0.4 ml/kg; Dose 2, 0.4 ml/kg; Dose 3, 3.8 ml/kg; and Dose 4, 13.1 ml/kg. PRE represents the value of MAP immediately prior to the infusion and POST represents the peak in MAP that generally occurred within 30 s of the end of the infusion. * signifies a statistically significant difference (p < 0.05) compared to baseline (PRE 2 mg/kg dose). † signifies a statistical significance (p < 0.01) compared to LP50A at the applied dose.